[Comparative clinical study of MF(mitomycin and 5-fluorouracil) and MF.BH-AC therapy].

Abstract

Sunrabim for injection (BH-AC), one of the antitumor agents available for acute leukemia, has considerable activity against a variety of transplanted solid tumors in rats and mice. A comparative clinical study was performed by randomized controlled trial on two different combined chemotherapies of MMC, 5-FU (MF group), and MMC, 5-FU, BH-AC (MF . BH-AC group) for 64 patients with a variety of solid cancers. Among 64 patients, 47 were evaluable for response (MF group: 23/32, MF . BH-AC group: 24/32). The partial response rate of the MF group was 4.3% (1/23), and that of the MF . BH-AC group was 33.3% (8/24). MF . BH-AC therapy was found to be more effective than MF therapy. The toxicity rates of the two therapies were similar (MF group: 46.7%, MF . BH-AC group: 50.0%). This study suggests that combined chemotherapy of MF plus BH-AC is more effective on a variety of solid cancers in comparison to MF therapy.

• Authors: H Satou, T Kamano, T Izumi, M Yoshida
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 9 Pg. 2807-12 (Sep 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3530137 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Mitomycins
• Cytarabine
• enocitabine
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Colonic Neoplasms (drug therapy)
• Cytarabine (administration & dosage, analogs & derivatives)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Mitomycins (administration & dosage)
• Neoplasms (drug therapy)
• Stomach Neoplasms (drug therapy)